Welcome to our dedicated page for Surgery Partners SEC filings (Ticker: SGRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Surgery Partners, Inc. (SGRY) SEC filings page provides access to the company’s regulatory disclosures as a Nasdaq-listed healthcare services company focused on short-stay and outpatient surgical care. Through these filings, investors can review detailed information about the business, its capital structure, governance and financial performance.
Surgery Partners’ annual reports on Form 10-K and quarterly reports on Form 10-Q describe its outpatient delivery model, the composition of its network of ambulatory surgery centers, surgical hospitals, multi-specialty physician practices and urgent care facilities, and the risks associated with operating in the healthcare sector. These reports also present audited and interim financial statements, management’s discussion and analysis, and risk factor disclosures related to reimbursement, regulation, physician relationships, supply chain, cybersecurity and indebtedness.
Current reports on Form 8-K highlight material events such as debt issuances, credit agreement amendments, earnings releases and leadership changes. For example, recent 8-K filings describe the issuance of additional 7.250% senior notes due 2032 by subsidiary Surgery Center Holdings, Inc., the execution of a second amendment to the company’s credit agreement establishing refinancing term loans and revolving credit commitments, and the announcement of quarterly financial results. Other 8-Ks report board and executive transitions, including resignations, appointments and related employment agreements.
Filings related to capital markets activity, such as indentures for senior notes and amendments to credit facilities, provide insight into interest rates, maturities, guarantees and covenants that shape Surgery Partners’ financial obligations. These documents are important for understanding leverage, refinancing plans and the structure of obligations at the operating subsidiary level.
On this page, AI-powered tools can help summarize lengthy filings, highlight key terms in debt agreements, and clarify the implications of earnings releases and non-GAAP measures like Adjusted EBITDA. Investors can use these summaries to quickly identify items such as revenue trends, same-facility performance, liquidity metrics, leverage ratios and governance changes, while still having direct access to the full text of Forms 10-K, 10-Q, 8-K and related exhibits filed with the SEC.
Surgery Partners, Inc. filed a Rule 144 notice to sell 14,574 common shares, listed as equity vesting transactions on 02/28/2026 (2,939 shares) and 03/02/2026 (11,635 shares).
Shares outstanding were 129,419,836 as of 03/06/2026, as shown in the excerpt.
Surgery Partners, Inc. notice of proposed sale of 272 common shares under equity compensation, dated 03/02/2026, with UBS Financial Services Inc. listed as the broker.
The filing also reports a prior sale of 1,794 common shares on 03/05/2026 by William T. Webb.
UBS Financial Services Inc filed a Form 144 notice for proposed sales of common stock of Surgery Partners, Inc. (SGRY). The filing lists equity-vesting related shares: 5,291 shares vested 02/28/2026 and 6,171 shares vested 03/02/2026. The filing date shown is 03/06/2026 and the listing venue is NASDAQ.
Surgery Partners, Inc. disclosure: a Form 144 notice lists 8,785 shares of common stock for sale on 03/06/2026 in connection with equity vesting. The filing shows two vesting entries: 1,738 shares (02/28/2026) and 7,047 shares (03/02/2026).
Surgery Partners, Inc. filed a Form 144 disclosing proposed sales of vested common shares by an affiliate/broker. The excerpt lists 1,039 shares vesting on 02/28/2026 and 6,697 shares vesting on 03/02/2026.
Transactions are presented as equity compensation vesting and proposed resale under Form 144.
Surgery Partners, Inc. filed a Form 144 notifying an intended sale of common stock, including 2,117 and 7,965 shares that vested on 02/28/2026. The filing lists UBS Financial Services Inc. as the broker on Nasdaq transactions.
Surgery Partners, Inc. reports that its surgical facilities generated approximately $3.2 billion in revenue during 2025, driven by a national network of more than 200 locations in 30 states, including 157 ambulatory surgery centers and 19 surgical hospitals.
The company focuses on high-volume, non-emergency outpatient procedures across specialties such as orthopedics, pain management, ophthalmology and gastroenterology, and pursues growth through physician partnerships, acquisitions, and new facility development. As of December 31, 2025, it owned or operated 176 surgical facilities and employed about 16,000 people.
Revenue is highly dependent on third-party payors: in 2025, consolidated surgical facilities derived 52.3% of patient service revenue from private insurance and 42.8% from government programs, with management highlighting significant exposure to Medicare, Medicaid, and evolving health policy. The filing also details regulatory and reimbursement risks, including the One Big Beautiful Bill Act’s Medicaid changes and the expiration of Affordable Care Act subsidies, which may increase the uninsured population and pressure margins.
Surgery Partners, Inc. reported higher 2025 revenue but remained unprofitable while setting cautious 2026 goals and launching a new share repurchase program.
Full-year 2025 revenue rose 6.2% to $3.31 billion, with same-facility revenue up 4.9% driven by 3.4% same-facility case growth and a 1.4% increase in revenue per case. Adjusted EBITDA increased 3.5% to $526.2 million, but net loss attributable to Surgery Partners was $77.9 million, though this improved from a larger loss in 2024.
Fourth-quarter 2025 revenue grew 2.4% to $885.0 million, while Adjusted EBITDA slipped 4.2% to $156.9 million, reflecting margin pressure. The company ended 2025 with $239.9 million of cash and total net debt to EBITDA of about 4.3x under its credit agreement.
For 2026, management targets Adjusted EBITDA of at least $530 million and revenue between $3.35 billion and $3.45 billion, implying modest organic growth after factoring provider tax and tariff headwinds. The board also authorized a new share repurchase program of up to $200 million of common stock, signaling confidence while the company focuses on higher-acuity procedures, portfolio optimization and reducing leverage.
Pentwater Capital Management LP and Matthew Halbower reported beneficial ownership of 10,000,000 shares of Surgery Partners, Inc. common stock, representing 7.7% of the class. This percentage is based on 129,341,779 shares outstanding as of November 3, 2025, as disclosed in the company’s Form 10-Q.
The shares are held through certain Pentwater funds, which have the right to receive dividends and sale proceeds. The reporting persons state that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Surgery Partners.